At NIG, we primarily focus in the use of Positron Emission Tomography (PET) molecular imaging, Magnetic Resonance Imaging (MRI), and Clinical observation to study common (Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis) and less common (Huntington’s disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal degeneration) neurodegenerative disorders.

We use a range of brain imaging techniques for investigating aetiology, pathophysiology, diagnosis, progression, identification of novel molecular targets for pharmacotherapy, and brain response to conventional, novel and restorative treatments in neurodegenerative disorders. We are hoping that with our projects we will help accelerate novel therapeutic development for neurodegenerative disorders.

We are carrying out projects by optimizing neuroimaging methodology and working towards identifying key mechanisms involved in neurodegeneration such as neuroinflammation, protein accumulation (e.g. tau, amyloid and α-synuclein), brain metabolic dysfunction and dysregulation of neurotransmitters and enzymes.